Stocks · News reference

8-K filing — ONCOLYTICS BIOTECH INC (ONCY)

Aug 18, 2026, 1:03 PMSEC EDGAR

Filed: 2026-08-18 AccNo: 0001129928-26-000053 Size: 165 KB Item 8.01: Other Events

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 19, 2026, 12:37 PMBenzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Oncolytics Biotech, Lowers Price Target to $5
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Oncolytics Biotech (NASDAQ:ONCY) with a Buy and lowers the price target from $10 to $5.
Read original at benzinga
ONCY
BenzingaAug 18, 2026, 1:03 PMBenzinga Newsdesk
Oncolytics Biotech Receives FDA Feedback On Design Of Potential Pivotal Part B Expansion Of REO 033, Its Ongoing Randomized Study Evaluating Pelareorep In Metastatic Colorectal Cancer; Company Believes Responses Represent Important Alignment Regarding Proposed Pivotal Study Design
Company received written feedback from the U.S. Food and Drug Administration ("FDA") regarding the design of a potential pivotal Part B expansion of REO 033, the Company’s ongoing randomized study evaluating
Read original at benzinga
ONCY
BenzingaJul 20, 2026, 1:01 PMBenzinga Newsdesk
Oncolytics Biotech Receives FDA's Fast Track Designation To Pelareorep In Combination With A Checkpoint Inhibitor Treat Squamous Cell Carcinoma Of Anal Canal
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company, today announced that the U.S. Food and Drug Administration ("FDA") has granted
Read original at benzinga
ONCY